Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CPMVNASDAQ:ENLVOTCMKTS:HPPINASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPMVMosaic ImmunoEngineering$0.54+9.0%$0.48$0.21▼$1.13$3.90M0.08194 shs100 shsENLVEnlivex Therapeutics$1.18+4.0%$1.03$0.81▼$1.76$27.79M0.79129,533 shs141,087 shsHPPIHedgePath Pharmaceuticals$0.05+14.8%$0.05$0.04▼$0.32$17.78M-1.1619,283 shs1,500 shsMTEXMannatech$9.30+0.5%$9.96$6.98▼$16.49$17.67M0.896,023 shs31,077 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPMVMosaic ImmunoEngineering+9.02%+49.44%+82.43%-17.23%-10.03%ENLVEnlivex Therapeutics+3.98%-2.89%+24.96%+32.32%-11.65%HPPIHedgePath Pharmaceuticals+2.35%+10.60%+10.42%-6.71%-39.24%MTEXMannatech+2.14%-1.59%-8.64%+11.38%+37.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics3.2076 of 5 stars3.75.00.00.00.00.80.6HPPIHedgePath PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech0.2985 of 5 stars0.03.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPMVMosaic ImmunoEngineering 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.33Buy$10.00751.06% UpsideHPPIHedgePath Pharmaceuticals 0.00N/AN/AN/AMTEXMannatech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CPMV, MTEX, HPPI, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.94) per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/A($0.01) per shareN/AMTEXMannatech$117.87M0.15$2.15 per share4.33$4.57 per share2.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPMVMosaic ImmunoEngineering-$920K-$0.12N/A∞N/AN/AN/A-1,117.89%8/12/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)HPPIHedgePath Pharmaceuticals-$4.55MN/A0.00∞N/AN/AN/A-246.03%N/AMTEXMannatech$2.49M-$0.10N/A∞N/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)Latest CPMV, MTEX, HPPI, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million4/15/2025Q4 2024CPMVMosaic ImmunoEngineeringN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/AN/AMTEXMannatechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPMVMosaic ImmunoEngineeringN/A0.020.02ENLVEnlivex TherapeuticsN/A7.207.20HPPIHedgePath PharmaceuticalsN/A6.766.76MTEXMannatech0.461.180.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPMVMosaic ImmunoEngineeringN/AENLVEnlivex Therapeutics1.02%HPPIHedgePath PharmaceuticalsN/AMTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipCPMVMosaic ImmunoEngineering80.99%ENLVEnlivex Therapeutics12.28%HPPIHedgePath Pharmaceuticals4.80%MTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableHPPIHedgePath Pharmaceuticals1370.45 millionN/ANot OptionableMTEXMannatech2501.90 million1.11 millionNot OptionableCPMV, MTEX, HPPI, and ENLV HeadlinesRecent News About These CompaniesMannatech names Peter Griscom as new chief operating officerJune 27, 2025 | investing.comMannatech Announces Promotion of Peter Griscom to Chief Operating Officer - MorningstarJune 27, 2025 | morningstar.comMMannatech appoints Peter Griscom COOJune 26, 2025 | msn.comMannatech Announces Promotion of Peter Griscom to Chief Operating OfficerJune 26, 2025 | businesswire.comMannatech Announces Results of Annual Shareholders’ MeetingJune 5, 2025 | finance.yahoo.comMannatech Announces Results of Annual Shareholders' MeetingJune 5, 2025 | businesswire.comMannatech Premieres Powerful New Documentary on Marathon Legend Steve EdwardsMay 21, 2025 | businesswire.comMannatech Reports Financial Results for First Quarter 2025May 13, 2025 | businesswire.comAstronova outlines fiscal 2026 growth targets driven by aerospace and PI segment advancementsApril 14, 2025 | msn.comMannatech Reports Fourth Quarter 2024 Financial ResultsMarch 26, 2025 | businesswire.comMannatech Stock Soars to 52-Week High, Hits $16 MarkJanuary 30, 2025 | msn.comMannatech names Robert Toth vice chairman of the boardNovember 27, 2024 | markets.businessinsider.comMannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of DirectorsNovember 26, 2024 | businesswire.comMannatech Inc. Q3 Earnings SummaryNovember 13, 2024 | markets.businessinsider.comMannatech Reports Financial Results for Third Quarter 2024November 12, 2024 | businesswire.comTrading (MTEX) With Integrated Risk ControlsOctober 17, 2024 | news.stocktradersdaily.comN(MTEX) Investment AnalysisOctober 6, 2024 | news.stocktradersdaily.comNMannatech, Incorporated (NASDAQ:MTEX) Director Sells $126,232.00 in StockSeptember 12, 2024 | insidertrades.comDirector Tyler Rameson Acquires 16,288 Shares of Mannatech Inc (MTEX)September 11, 2024 | finance.yahoo.com(MTEX) Trading SignalsAugust 18, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPMV, MTEX, HPPI, and ENLV Company DescriptionsMosaic ImmunoEngineering OTCMKTS:CPMV$0.54 +0.04 (+9.02%) As of 07/3/2025 12:36 PM EasternMosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Enlivex Therapeutics NASDAQ:ENLV$1.18 +0.05 (+3.98%) Closing price 07/3/2025 02:39 PM EasternExtended Trading$1.18 0.00 (0.00%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.HedgePath Pharmaceuticals OTCMKTS:HPPI$0.05 +0.01 (+14.83%) As of 07/2/2025HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.Mannatech NASDAQ:MTEX$9.30 +0.05 (+0.54%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
